No clinical relevant changes in efficacy, quality of life and tolerability for RA patients in clinical remission 16 weeks after switching to the biosimilar IFX CT-P13 compared to the originator; a descriptive report

Authors
Category Primary study
JournalAnnals of the Rheumatic Diseases
Year 2019
This article has no abstract
Epistemonikos ID: 68505826e533a313a08399f1c798d2ab3cba6214
First added on: Feb 11, 2025